Home Ingredients Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)
Weight ManagementMetabolic Health

Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)

Capsicum annum
Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

Capsifen® is Akay Bioactives' red chili (Capsicum annum) capsaicinoid complex delivered via FenuMat® technology — fenugreek galactomannan beadlets that encapsulate capsaicinoids in self-emulsifying hydrogel form. Standardized to 2.1% total capsaicinoids (capsaicin + dihydrocapsaicin + nordihydrocapsaicin). The FenuMat delivery delivers 19× higher serum bioavailability of 'free' (unconjugated) capsaicinoids vs standard capsaicin extracts, with pungency masked — solving the fundamental challenge of capsaicinoid supplementation (burning sensation and stomach discomfort at effective doses). The pivotal trial (Roopashree 2024, Frontiers in Nutrition, doi:10.3389/fnut.2024.1348328) was a 3-arm randomized double-blind placebo-controlled crossover in 105 healthy overweight participants over 28 days: 100 mg and 200 mg doses produced dose-dependent 4.8% and 6.2% weight reductions, increased energy expenditure, fat oxidation (measured via Quark C-PET cardiopulmonary exercise testing), endurance/time to exhaustion, and body temperature elevation (+1-2°C). Critically, no adverse events: no increased heart rate, palpitations, sweating, or abdominal pain. Honest framing: well-designed recent trial in a relevant population; the bioavailability and tolerability advantages over plain capsaicin are clinically meaningful.

Studied Dose 100-200 mg/day Capsifen (Roopashree 2024 trial protocol). The 200 mg/day dose produced larger effects in the 3-arm crossover (6.2% weight reduction vs 4.8% at 100 mg). 28-day duration sufficient for measurable energy expenditure and weight outcomes. Earlier safety study established 200 mg/day as bioavailable and safe in individuals with obesity. Take with food for optimal absorption from the FenuMat matrix.
Active Compound Capsicum annum (red chili) capsaicinoid extract encapsulated in Akay's FenuMat® matrix (fenugreek-derived soluble galactomannan beadlets, self-emulsifying hydrogel). Standardized to 2.1% total capsaicinoids: capsaicin, dihydrocapsaicin (DC), and nordihydrocapsaicin (NDC). Capsaicinoid content quantified by validated HPLC with photodiode array detection.

Benefits

Dose-dependent weight reduction (Roopashree 2024)

3-arm randomized double-blind placebo-controlled crossover trial in 105 healthy overweight participants over 28 days. Outcomes: 4.8% weight reduction at 100 mg/day Capsifen and 6.2% at 200 mg/day vs baseline. Clear dose-response. Published in Frontiers in Nutrition 2024 (doi:10.3389/fnut.2024.1348328).

Supported by Trial 1

Increased energy expenditure

Same trial documented increased energy expenditure at both Capsifen doses vs placebo, measured via Quark C-PET (validated cardiopulmonary exercise test system). Increased EE is the primary mechanism through which capsaicinoids influence body weight — increased calorie burn rather than appetite suppression.

Supported by Trial 1, Trial 2

Enhanced fat oxidation

Respiratory quotient analysis revealed reductions in both resting and exercise-induced RQ values in Capsifen groups — indicating shifted substrate utilization toward fat oxidation vs carbohydrate oxidation. Mechanism for body composition changes beyond simple energy balance.

Supported by Trial 1, Trial 2

Improved endurance performance

Time to exhaustion (endurance) significantly improved in Capsifen groups vs placebo. Positions Capsifen as a dual-use ergogenic aid — useful for both weight management and athletic performance support.

Supported by Trial 1

19× higher free capsaicinoid bioavailability

FenuMat delivery achieves 19× higher serum bioavailability of 'free' (unconjugated, bioactive) capsaicinoids vs standard capsaicin extracts. The 'free' fraction matters because conjugated capsaicin metabolites have reduced biological activity. This enables clinical efficacy at the low 100-200 mg/day doses with masked pungency.

Supported by Trial 1, Trial 2

Pungency-free with no GI adverse events

Critical practical advantage: no increased heart rate, palpitations, sweating, or abdominal pain reported in the 105-participant trial despite clear thermogenic efficacy (+1-2°C body temperature elevation). FenuMat beadlets enable sustained intestinal release that bypasses the gastric irritation that limits standard capsaicin supplementation.

Supported by Trial 1

Mechanism of action

1

TRPV1 receptor activation (thermogenesis)

Capsaicinoids activate the TRPV1 (vanilloid receptor 1) thermal-sensing ion channel in sensory neurons. Activation triggers sympathetic nervous system activity and brown adipose tissue thermogenesis — the body's primary metabolic heat generation mechanism. Drives the +1-2°C body temperature elevation and increased energy expenditure.

2

Fat oxidation pathway upregulation

TRPV1 activation upregulates fatty acid oxidation enzymes (CPT1, ACO) and downregulates lipogenesis. Net effect: more fat used as fuel, less stored. Measurable in the Roopashree trial as reduced respiratory quotient (more fat vs carbs oxidized).

3

Catecholamine release

Capsaicinoid-triggered sympathetic activation releases catecholamines (norepinephrine, epinephrine) which mobilize fatty acids from adipose tissue and increase basal metabolic rate. The same pathway underlies caffeine and other thermogenic ingredients, but capsaicin operates via a distinct receptor (TRPV1) without adenosine antagonism.

4

FenuMat sustained intestinal release

Fenugreek galactomannan beadlets form a self-emulsifying hydrogel in the intestinal environment, delivering capsaicinoids slowly to the small intestinal lumen — bypassing the gastric mucosa where direct capsaicin exposure causes the characteristic burn. Sustained release also extends the duration of TRPV1 stimulation.

Clinical trials

1
Capsifen 28-Day Crossover Trial — Roopashree 2024

Randomized double-blind placebo-controlled 3-arm 3-sequence crossover trial in 105 healthy overweight adults. Arms: placebo, Capsifen 100 mg/day, Capsifen 200 mg/day, each for 28 days. Outcomes: dose-dependent weight reduction (4.8% and 6.2%), increased energy expenditure, increased fat oxidation (reduced respiratory quotient), improved time to exhaustion, body temperature elevation +1-2°C. No adverse events including no tachycardia, palpitations, sweating, or GI symptoms. Published in Frontiers in Nutrition 2024 (doi:10.3389/fnut.2024.1348328).

2
Capsifen Safety Assessment — Joseph 2020

Acute (14-day) and sub-chronic (90-day) toxicity studies in Wistar rats. Capsifen administration produced no significant changes in food/water consumption, hematological or biochemical parameters. Histopathology showed no morphological abnormalities. Body weight showed mild decreasing trend at high doses (500-1,000 mg/kg) consistent with thermogenic mechanism. Established safety basis for human clinical trials. Published 2020 (PMC7229275).

Side effects and drug interactions

Common Potential side effects

Excellent tolerability profile in the Roopashree 2024 trial — no GI symptoms, no cardiovascular adverse events.
Fenugreek allergy concern — FenuMat is fenugreek-derived; individuals with fenugreek/legume allergy should avoid.
Theoretical sensitivity to capsaicinoids in individuals with active GERD, peptic ulcer disease, or IBS flares (though sustained intestinal release reduces this concern vs standard capsaicin).
Mild body temperature elevation expected — feature of the mechanism, not a side effect.
Pregnancy and lactation — safety data lacking; avoid.

Important Drug interactions

Antihypertensives — capsaicinoids modestly activate sympathetic nervous system; theoretical interaction with blood pressure medications; monitor BP if combined.
Stimulant medications — additive sympathomimetic effects possible with caffeine, ephedrine, ADHD medications; use caution.
Anticoagulants — capsaicinoids may have mild antiplatelet activity; monitor INR with warfarin.
ACE inhibitors — rare reports of cough exacerbation with high capsaicin intake.
Pregnancy and lactation — avoid; safety not established at supplemental doses.

More Weight Management Ingredients

Antioxidant
Green Tea
Green tea extract, derived from Camellia sinensis leaves, is rich in antioxidants like cat…
Metabolic Health
Berberine
Berberine is a bioactive compound extracted from plants like barberry and goldenseal, know…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol acting as a secondary messenger in insulin…
Weight Management
Capsaicin / Capsicum Extract (Capsimax®)
Capsaicin is the primary bioactive compound in hot peppers, responsible for their heat and…

Explore Other Ingredients

Cognitive
Rhodiola Rosea
Rhodiola rosea is an adaptogenic herb from arctic and mountainous regions of Europe and As…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a lipid-soluble compound essential to mitochondrial ATP production…
Muscle & Recovery
Magnesium
Magnesium is the fourth most abundant mineral in the body and a cofactor for over 300 enzy…

Frequently asked questions about Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)

What is Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)?

Capsifen® is Akay Bioactives' red chili (Capsicum annum) capsaicinoid complex delivered via FenuMat® technology — fenugreek galactomannan beadlets that encapsulate capsaicinoids in self-emulsifying hydrogel form.

What does Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) do?

Capsaicinoids activate the TRPV1 (vanilloid receptor 1) thermal-sensing ion channel in sensory neurons. Activation triggers sympathetic nervous system activity and brown adipose tissue thermogenesis — the body's primary metabolic heat generation mechanism. In clinical research, Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) has been studied for dose-dependent weight reduction (roopashree 2024), increased energy expenditure, enhanced fat oxidation.

Who should take Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)?

Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) may be most relevant for people interested in weight management, metabolic health. It has been clinically studied for dose-dependent weight reduction (roopashree 2024), increased energy expenditure, enhanced fat oxidation. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) take to work?

In clinical trials, effects have been measured at 28 days of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)?

Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) can typically be taken with breakfast or dinner — taking with food reduces GI sensitivity for most supplements. Specific timing matters less than daily consistency for cumulative effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) worth taking?

Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives)?

The clinically studied dose for Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) is 100-200 mg/day Capsifen (Roopashree 2024 trial protocol). The 200 mg/day dose produced larger effects in the 3-arm crossover (6.2% weight reduction vs 4.8% at 100 mg). 28-day duration sufficient for measurable energy expenditure and weight outcomes. Earlier safety study established 200 mg/day as bioavailable and safe in individuals with obesity. Take with food for optimal absorption from the FenuMat matrix.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) used for?

Capsifen® (Bioavailable Capsaicinoids via FenuMat® — Akay Bioactives) is studied for dose-dependent weight reduction (roopashree 2024), increased energy expenditure, enhanced fat oxidation. 3-arm randomized double-blind placebo-controlled crossover trial in 105 healthy overweight participants over 28 days. Outcomes: 4.8% weight reduction at 100 mg/day Capsifen and 6.2% at 200 mg/day vs baseline. Clear dose-response.